A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).
about
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic AgentsImaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast CancerMolecular Imaging of Biomarkers in Breast CancerDevelopment of Companion DiagnosticsThe preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients.Pharmacodynamic imaging guides dosing of a selective estrogen receptor degraderComparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change afFailed PET Application Attempts in the Past, Can We Avoid Them in the Future?64Cu-Labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor.Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers.Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.High specific activity is not optimal: 18 F-fluoroestradio positron emission tomography-computed tomography results in a breast cancer xenograft.Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy.Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: a cost-effectiveness study.
P2860
Q26740567-3C169F5D-5F8E-44D2-BE25-DDD1B72713A3Q26772868-69FC0D5D-1C86-42F7-A501-DD5FE7B7E7A9Q26772870-3C4895EC-0E2E-42CE-B709-78CADC3D15C1Q26774670-BA7B85DB-FDE3-49A5-A022-6B911E36230EQ35009047-45D0D4F4-5E04-46CF-9B96-9B741B9D2869Q35178385-0F865A18-96C8-4E5A-B210-06CFB1803C50Q36088779-11F63ADE-BF28-4369-B0DB-72F5135FF2F8Q38411841-D7010E63-09A1-477B-BB49-67B5EB552D31Q38800009-6CF723D1-2564-462B-95C8-8E9DABF76A89Q38815325-39BFCEE2-5DF7-4704-B1F6-D508F03E9B57Q38838285-3B78FE2E-2356-436F-966C-C4AAAB4F3051Q39656587-260B14E5-C458-4ACD-ADA2-7F9AF6FE6C4DQ40409656-5BD59129-CDFA-4D9A-A6E4-25346BB39D84Q48301796-1105958D-B370-44A2-A0DF-6FB7E830B141Q51311647-2A7EEEDD-6E30-40CE-890F-237EEB5DC902Q55040337-D04BB63C-3CE8-4884-83C5-A850F615C849
P2860
A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
A phase 2 study of 16α-[18F]-f ...... etastatic breast cancer (MBC).
@en
A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography
@nl
type
label
A phase 2 study of 16α-[18F]-f ...... etastatic breast cancer (MBC).
@en
A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography
@nl
prefLabel
A phase 2 study of 16α-[18F]-f ...... etastatic breast cancer (MBC).
@en
A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography
@nl
P2093
P2860
P1476
A phase 2 study of 16α-[18F]-f ...... metastatic breast cancer (MBC)
@en
P2093
David A Mankoff
Erin K Schubert
Hannah M Linden
Janet F Eary
Jeanne M Link
Lalitha K Shankar
Lanell M Peterson
Peggy Porter
P2860
P2888
P304
P356
10.1007/S11307-013-0699-7
P577
2013-10-30T00:00:00Z